The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer

Authors

  • Emir Sokolović Public Institution Medical Center of Canton Sarajevo, Sarajevo
  • Timur Cerić Clinic of Oncology, Clinical Center University of Sarajevo, Sarajevo
  • Šejla Cerić Clinic of Nuclear Medicine, Clinical Center University of Sarajevo, Sarajevo
  • Semir Bešlija Clinic of Oncology, Clinical Center University of Sarajevo, Sarajevo
  • Sandra Vegar-Zubović Clinic of Radiology, Clinical Center University of Sarajevo, Sarajevo
  • Nermina Bešlić Clinic of Nuclear Medicine, Clinical Center University of Sarajevo, Sarajevo
  • Irmina Sefić-Pašić Clinic of Radiology, Clinical Center University of Sarajevo, Sarajevo
  • Anes Pašić Clinic of Oncology, Clinical Center University of Sarajevo

DOI:

https://doi.org/10.5644/ama2006-124.278

Keywords:

PET/CT, SUVmax, Colorectal Cancer, CA 19-9, Progression Free Survival

Abstract

Objective. The aim of the study was to evaluate the prognostic value of the maximum standardized uptake value (SUVmax) of 18F-Fluorodeoxyglucose (18F-FDG) PET/CT in patients with metastatic colorectal cancer, and to compare it with classical prognostic markers.

Materials and Methods. The study included 70 patients with metastatic colorectal cancer who had not been treated for the metastatic disease. The patients underwent 18F-FDG PET/CT as part of their routine diagnostic reevaluation. During the analysis, the value of the largest tumor diameter and SUVmax was determined for the lesion with the highest SUVmax observed. The values of CEA and CA 19-9 were recorded 7 days before the PET/CT analysis.

Results. SUVmax and Carbohydrate antigen (CA)19-9 were found to be independent prognostic markers of disease progression within 12 months. Based on the Receiver Operating Characteristics (ROC) curve analysis, the patients could be divided into two groups: SUVmax≤4.1 vs. SUVmax>4.1. Patients with SUVmax values of 4.1 or less had significantly better progression-free survival within 12 months with an HR (95% CI) of 2.97 (1.4-6.3), relative to patients with SUVmax values above 4.1.

Conclusion. SUVmax may be used as a novel prognostic marker of disease progression among patients with metastatic colorectal cancer. Values of SUVmax can be used to select patients with a more aggressive type of disease and higher risk for progression within 12 months of PET/CT analysis.

Downloads

Download data is not yet available.
Gisela Januszewska, née Rosenfeld

Downloads

Published

2020-08-01

How to Cite

Sokolović, E., Cerić, T., Cerić, Šejla, Bešlija, S., Vegar-Zubović, S., Bešlić, N., Sefić-Pašić, I., & Pašić, A. (2020). The Prognostic Value of SUVmax of 18F-FDG PET/CT in Patients with Metastatic Colorectal Cancer. Acta Medica Academica, 49(1), 1–8. https://doi.org/10.5644/ama2006-124.278

Issue

Vol. 49 No. 1 (2020)

Section

Clinical Science

Most read articles by the same author(s)